Profile
Will Greenleaf is the founder of Protillion Biosciences, Inc. He is also the founder of Epinomics, Inc.
Will Greenleaf active positions
| Companies | Position | Start |
|---|---|---|
Epinomics, Inc.
 Epinomics, Inc. Packaged SoftwareTechnology Services Epinomics, Inc. provides decoding programming of genome to drive personalized medicine. The company was founded by Paul Giresi, Fergus Chan, Howard Y. Chang and Will Greenleaf and is headquartered in Menlo Park, CA. | Founder | - |
Former positions of Will Greenleaf
| Companies | Position | End |
|---|---|---|
Protillion Biosciences, Inc.
 Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Epinomics, Inc.
Epinomics, Inc. Packaged SoftwareTechnology Services Epinomics, Inc. provides decoding programming of genome to drive personalized medicine. The company was founded by Paul Giresi, Fergus Chan, Howard Y. Chang and Will Greenleaf and is headquartered in Menlo Park, CA. | Technology Services |
Protillion Biosciences, Inc.
Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | Health Technology |
- Stock Market
- Insiders
- Will Greenleaf
